Boundless Bio, Inc. — Investor Relations & Filings

Boundless Bio, Inc. is a clinical-stage precision oncology company focused on developing therapies for patients with oncogene amplified cancers. The company's approach is centered on understanding and targeting extrachromosomal DNA (ecDNA), a key driver of oncogene amplification, tumor progression, and treatment resistance in many intractable cancers. By exploiting the unique vulnerabilities of cancer cells that rely on ecDNA, Boundless Bio is advancing a pipeline of ecDNA-directed therapies (ecDTx). The company aims to provide novel, life-improving treatment options for a patient population with significant unmet medical needs, as cancers driven by oncogene amplification are often unresponsive to existing targeted therapies and immunotherapies.